Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02511639
What this trial is testing

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer Metastatic
Istituto Oncologico Veneto IRCCS 110
Not applicableUnknownNCT06344780
What this trial is testing

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 200
Not applicableStudy completedNCT07086196
What this trial is testing

Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 350
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)Study completedNCT03222856
What this trial is testing

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Who this might be right for
Breast Cancer
MedSIR 44
Not applicableStudy completedNCT04943497
What this trial is testing

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,390
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Testing effectiveness (Phase 2)Looking for participantsNCT06611813
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Looking for participantsNCT07198724
What this trial is testing

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more
Kristina A. Fanucci 65
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07254858
What this trial is testing

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Wenzhou Medical University 302
Testing effectiveness (Phase 2)Looking for participantsNCT06374459
What this trial is testing

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Who this might be right for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine 152
Testing effectiveness (Phase 2)Ended earlyNCT04862143
What this trial is testing

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 2
Testing effectiveness (Phase 2)UnknownNCT05512416
What this trial is testing

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
The Affiliated Hospital of Qingdao University 35
Not applicableLooking for participantsNCT06774027
What this trial is testing

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Who this might be right for
HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast Cancer+3 more
University of California, San Francisco 100
Not applicableStudy completedNCT02023359
What this trial is testing

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Healthcare A/S 7
Not applicableNot Yet RecruitingNCT07543250
What this trial is testing

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer
xuliang 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04895358
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 342
Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Next Page